• 1. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 2. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 3. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 4. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 5. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110

The Compound CAS No. 1093860-45-7: (1-Methyl-1H-indazol-3-yl)methylamine Dihydrochloride

The compound with CAS No. 1093860-45-7, commonly referred to as (1-Methyl-1H-indazol-3-yl)methylamine dihydrochloride, is a fascinating molecule that has garnered significant attention in the fields of organic chemistry and pharmacology. This compound belongs to the class of indazole derivatives, which are known for their diverse biological activities and potential applications in drug discovery. The indazole core of this molecule is a bicyclic structure consisting of a benzene ring fused to an imidazole ring, which contributes to its unique chemical properties.

Recent studies have highlighted the importance of indazole derivatives in medicinal chemistry, particularly in the development of kinase inhibitors and other therapeutic agents. The methylamine group attached to the indazole ring in this compound adds further functional complexity, potentially enhancing its bioavailability and pharmacokinetic properties. The dihydrochloride salt form of this compound suggests that it may be used in pharmaceutical formulations where a specific pH or solubility profile is required.

One of the most promising applications of (1-Methyl-1H-indazol-3-yl)methylamine dihydrochloride lies in its potential as a lead compound for anti-cancer drug development. Researchers have demonstrated that certain indazole derivatives exhibit selective cytotoxicity against various cancer cell lines, making them valuable candidates for further investigation. The methylamine group in this compound may play a critical role in modulating its interaction with cellular targets, such as protein kinases or other enzymes involved in oncogenesis.

In addition to its therapeutic potential, this compound has also been explored for its role in chemical synthesis and catalysis. The indazole framework is known to act as a versatile scaffold for constructing more complex molecules, and the presence of the methylamine group provides additional sites for functionalization. Recent advancements in asymmetric synthesis techniques have enabled the preparation of enantiomerically pure forms of this compound, which are essential for studying its stereochemical effects on biological activity.

From a structural standpoint, the (1-Methyl-1H-indazol-3-yl)methylamine dihydrochloride molecule exhibits a balance between hydrophobic and hydrophilic regions, which is crucial for its interaction with biological systems. The indazole ring contributes aromaticity and planarity to the molecule, while the methylamine group introduces hydrogen bonding capabilities. These properties make it an interesting candidate for studying molecular recognition and receptor-ligand interactions.

Recent research has also focused on the environmental fate and toxicity of this compound. Understanding its degradation pathways and bioaccumulation potential is essential for ensuring its safe use in pharmaceutical applications. Studies have shown that the dihydrochloride salt form may influence its stability under various environmental conditions, highlighting the need for further investigation into its ecological impact.

In conclusion, (1-Methyl-1H-indazol-3-yl)methylamine dihydrochloride (CAS No. 1093860-45-7) represents a valuable addition to the arsenal of compounds being explored for their therapeutic potential. Its unique chemical structure, combined with recent advances in synthetic methodologies and biological studies, positions it as a promising lead compound for future drug development efforts.

• 440099-33-2((1-Methyl-1H-indazol-3-yl)methanamine hydrochloride)
• 124491-38-9(methyl(1-methyl-1H-indazol-3-yl)methylamine)
• 117891-16-4((1H-Indazol-3-YL)methylamine hydrochloride)
• 1060817-08-4(1-(1,5-Dimethyl-1H-indazol-3-yl)methanamine)
• 739359-10-5(1-Methyl-1H-indazole-3-methanamine)
• 1195264-69-7((1H-indazol-3-yl)methanamine dihydrochloride)
• 34879-84-0(1,3-Dimethyl-1H-indazole)
• 881388-09-6(1H-Indeno[6,7,1-def]cinnoline, 1,3-dimethyl-)
• 1033693-10-5(1-(4-chloro-1-methyl-1H-indazol-3-yl)methanamine)
• 115705-38-9(Benzo[1,2-c:5,4-c']dipyrazole, 1,7-dihydro-1,3,5,7-tetramethyl-)